Phathom Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal (GI) diseases. The company was established in 2018 to develop and market vonoprazan, a first-in-class oral small molecule potassium-competitive acid blocker (PCAB). Its commercial portfolio includes VOQUEZNA tablets for the treatment of erosive and non-erosive gastroesophageal reflux disease (GERD), as well as VOQUEZNA TRIPLE PAK and DUAL PAK for the treatment of Helicobacter pylori infections. Phathom holds the exclusive rights to vonoprazan in the United States, Europe, and Canada, and is actively commercializing the drug in the U.S. market. The company is also advancing clinical trials to expand vonoprazan's indications, including potential treatments for eosinophilic esophagitis (EoE) and other acid-related disorders.
